Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial. [PDF]
Agostini HT +9 more
europepmc +1 more source
Transient vitreous opacity following combined intravitreal injection of pegcetacoplan and faricimab-svoa in patients with neovascular age-related macular degeneration and geographic atrophy. [PDF]
Zhang Y, Wei C, Stewart JM.
europepmc +1 more source
Ranibizumab on optic disc perfusion in central retinal vein occlusion. [PDF]
Li X, Hao XF, Xie LK, Luo JH, Zhang MJ.
europepmc +1 more source
Fluorescence lifetime imaging ophthalmoscopy (FLIO) of patients with neovascular age-related macular degeneration before and after treatment with intravitreal ranibizumab. [PDF]
Sonntag SR +4 more
europepmc +1 more source
Trends in Anti-Vascular Endothelial Growth Factor Injections Among Medicare Part B Beneficiaries in 2013-2021 and the Step Therapy Era. [PDF]
Bryan JM, Sheth N, Heiferman MJ.
europepmc +1 more source
Budget Impact of Faricimab in Neovascular Age-Related Macular Degeneration in the Netherlands: A Systematic Review and Meta-Analysis of Injection Count. [PDF]
El Alili M +5 more
europepmc +1 more source
Antibody-based therapeutics and therapeutic development for diabetic retinopathy: targeting VEGF, Ang/Tie, and inflammatory pathways. [PDF]
Zong Y +6 more
europepmc +1 more source
Antiangiogenic Drugs in Age Related Macular Degeneration: evidence based medicine and off-label use [PDF]
Cachulo, ML +6 more
core
Short-Term Effects of Intravitreal Ranibizumab Biosimilar Injections in Patients with Neovascular Age-Related Macular Degeneration on Retinal Nerve Fiber Layer Thickness. [PDF]
Lee SY, Hwang DD.
europepmc +1 more source
Safety of íntravitreal panitumumab combined with intravitreal ranibizumab in rabbits. [PDF]
Bikbov MM +6 more
europepmc +1 more source

